Transcatheter heart valves technologies

TAVR operator volumes, trends, and geographic variations amongst Medicare beneficiaries in the United States

Published on 10/03/2022 | Timothy F. SimpsonMD et al. | Catheterization and Cardiovascular Interventions 2022; AOP: 10.1002/ccd.30134 | 9 minute read

Abstract Objectives To evaluate transcatheter aortic valve replacement (TAVR) operator procedural volumes, and describe temporal and geographic trends.Background TAVR is

Transcatheter heart valves technologies

Peripheral access size evaluation in transfemoral transcatheter aortic valve replacement

Published on 24/02/2022 | Irbaz HameedMD 1 et al. | Journal of Cardiac Surgery 2022; AOP: 10.1111/jocs.16293 | 16 minute read

Abstract Background/Aim Peripheral access vessel dimensions in the general patient population screened for transcatheter aortic valve replacement (TAVR) can offer

Transcatheter heart valves technologies

Current and future transcatheter aortic valve replacement valves

Published on 24/02/2022 | Eikelboom et al. | Current Opinion in Cardiology 2022; 37(2): 173-9 | 15 minute read

Abstract Purpose of review This review analyzes currently available commercial transcatheter aortic valve replacement (TAVR) valves as well as valves

Transcatheter heart valves technologies

Temporal Trends and Drivers of Heart Team Utilization in Transcatheter Aortic Valve Replacement: A Population‐Based Study in Ontario, Canada

Published on 10/02/2022 | Gil Marcus MD 1 et al. | Journal of the American Heart Association 2021; 10(13): 020741 | 18 minute read

Abstract Background The multidisciplinary Heart Team (HT) is recommended for management decisions for transcatheter aortic valve replacement (TAVR) candidates, and

Transcatheter heart valves technologies

Muscle fat index is associated with frailty and length of hospital stay following transcatheter aortic valve replacement in high-risk patients

Published on 27/01/2022 | Heidari et al. | International Journal of Cardiology 2022; 348(1 February 2022): 33-8 | 0 minute read

Transcatheter heart valves technologies

The impact of pulmonary hypertension on outcomes of transcatheter mitral valve replacement in mitral annular calcification

Published on 27/01/2022 | Hector R. CajigasMD 1 et al. | Catheterization and Cardiovascular Interventions 2022; AOP: 10.1002/ccd.30057 | 16 minute read

Abstract Objectives To assess the impact of pulmonary hypertension (PH) on outcomes of patients with severe mitral annular calcification (MAC)

Transcatheter heart valves technologies

Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?

Published on 20/01/2022 | GiulioRusso @giuliorus 1 et al. | European Journal of Heart Failure 2021; AOP: 10.1002/ejhf.2398 | 41 minute read

Abstract Tricuspid regurgitation (TR) is a highly prevalent valvular heart disease and is associated with an increased risk of cardiovascular

Transcatheter heart valves technologies

Radial versus femoral secondary access for transcatheter aortic valve replacement: A systematic review and meta‐analysis

Published on 20/01/2022 | Thomas M.DasMD 1 et al. | Catheterization and Cardiovascular Interventions 2021; AOP: 10.1002/ccd.30009 | 16 minute read

Abstract Objectives We aimed to evaluate the risk of procedural complications after TAVR using secondary radial access (RA) versus femoral

Transcatheter heart valves technologies

Proposal criteria of paradoxical low-flow low-gradient aortic stenosis for predicting prognosis in patients undergoing transcatheter aortic valve implantation

Published on 20/12/2021 | Tomomi Tanino 1 et al. | Heart and Vessels 2021; aop: 10.1007/s00380-021-01992-y | 21 minute read

Abstract Background Paradoxical low-flow, low-gradient (PLF-LG) aortic stenosis (AS) is associated with poor prognosis in patients undergoing transcatheter aortic valve

Transcatheter heart valves technologies

Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis

Published on 20/12/2021 | Stephanie Louise Swift 1 et al. | BMJ Open 2021; 11(12): e054222 | 47 minute read

Abstract Objectives Patients undergoing surgery for severe aortic stenosis (SAS) can be treated with either transcatheter aortic valve implantation (TAVI)

This bibliographical database is provided by GNM Healthcare Group Companies USA, Inc. in full editorial independence.

The information published within the framework of this service may discuss or suggest certain therapies that have not been validated by the competent national authorities.
Service exclusively reserved for healthcare professionals.